KYLYS, a Life Science spin-off from the University of Geneva, was founded in March 2017. Driven by a passion for science and biotechnology, we are dedicated to developing a unique technology for delivering highly effective and safe products based on hyaluronic acid (HA).

Our product lines include medical treatments (KYLYS) and aesthetic solutions (KYLYS AESTHETICS).

Enhancing safety and precision with our next-generation Hyaluronic Acid-based product, designed to minimize post-injection side effects and maximize comfort. Currently available commercial products of water-soluble polymers suffer from a very short lifespan within the body. Their excessively fast elimination is a clear drawback. Our product, HA-L-PNIPAM, is an entirely new biocompatible and biodegradable gel that is extremely easy to inject as a fluid gel at room temperature. It has an exceptional ability to form microgel structures in the tissue at body temperature, providing an unprecedented durable effect and absence of migration from the injection site. The microgel structures formed by HA-L-PNIPAM upon exposure to body temperature act as barriers against degradation by endogenous enzymes or oxidation.